Pharmaceutical
Health
Therapy

Zogenix

$37.39
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.31 (-0.82%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Zogenix and other stocks, options, ETFs, and crypto commission-free!

About

Zogenix, Inc. Common Stock, also called Zogenix, is a pharmaceutical compan. Read More It engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include ZX008 and Relday. The company was founded by Stephen James Farr, Cam L. Garner, Roger L. Hawley, Bret E. Megargel, Jonathan M. N. Rigby, Scott L. Glenn, and John J. Turanin on May 11, 2006 and is headquartered in Emeryville, CA.

Employees
90
Headquarters
Emeryville, California
Founded
2006
Market Cap
1.59B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
664.93K
High Today
$38.09
Low Today
$37.05
Open Price
$37.42
Volume
170.03K
52 Week High
$62.75
52 Week Low
$33.43

Collections

Pharmaceutical
Health
Therapy
Technology

News

Yahoo FinanceMay 13

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ZGNX, INVVY and S

NEW YORK, NY / ACCESSWIRE / May 13, 2019 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies.

64
Yahoo FinanceMay 9

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Zogenix, Inc. To Contact The Firm

114
Seeking AlphaMay 8

Zogenix, Inc. (ZGNX) CEO Stephen Farr on Q1 2019 Results - Earnings Call Transcript

Zogenix, Inc. (NASDAQ:ZGNX) Q1 2019 Results Earnings Conference Call May 8, 2019 4:30 PM ET Company Participants Brian Ritchie - LifeSci Advisors Stephen Farr - Chief Executive Officer Michael Smith - Chief Financial Officer Gail Farfel - Chief Development Officer Ashish Sagrolikar - Chief Commercial Officer Conference Call Participants Marc Goodman - SVB Leerink Jason Butler - GMP Securities Difei Yang - Mizuho Securities Yatin Suneja - Guggenheim Partners Operator Greetings, and welcome to th...

63

Earnings

-$1.53
-$1.20
-$0.86
-$0.53
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
-$0.83 per share
Actual
-$0.83 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.